Vodis appoints Pelosi, Boulton to board
(firmenpresse) - Vodis appoints Pelosi, Boulton to board
VODIS PHARMACEUTICALS INC. ANNOUNCES ADDITION OF PAUL PELOSI JR. AND CLIVE BOULTON TO THE BOARD OF DIRECTORS
Paul Pelosi Jr. and Clive Boulton have agreed to join the board of directors of Vodis Pharmaceuticals Inc.
Otto Folprecht, Chief Executive Officer and Director of Vodis, states: "We are extremely pleased that these gentlemen, with their extensive background and track record of accomplishment in government, business and law have decided to join the Board of Directors for Vodis. Their combined public and private sector expertise will be an asset as the Company moves forward on its vision to be one of the leading companies in the marijuana sector in Canada and the United States of America."
Mr. Paul Francis Pelosi, Jr. is a graduate of Georgetown University with a Bachelor of Arts in History (Cum Laude) and a JD/MBA (Joint Degree) with an emphasis on Human Rights and International Business. Mr. Pelosi has many experiences as a Director or Advisor to companies regarding strategic planning, sustainability and efficiency. Mr. Pelosi is a member of California State Bar, a California Real Estate Broker, and a Registered Securities Representative. Mr. Pelosi currently serves on the Board of Directors for LookSmart, Inc. and Targeted Medical. Mr. Pelosi has also worked with government organizations, including NASA and the City of San Francisco. Prior to independent consulting, Mr. Pelosi served many years with Bank of America Securities, Bank of America Countrywide and JP Morgan - Chase Manhattan where he worked in Corporate Finance, Institutional Sales, and the Residential Mortgage Industry. Working with a combination of public and private organizations, Mr. Pelosi has focused on improving living conditions by foundation programs like the Cisco Connected Urban Development that developed policies and programs in recycling, toxics reduction, environmental justice, energy efficiency, and commute alternatives
Clive Boulton has been practising law since 1979, first at the Provincial Crown Counsel's office in Vancouver to gain trial experience after finishing his articles. For two years he did exclusively trial work in Provincial and Supreme Court and spent six months doing jury trials.In 1981, Mr. Boulton entered private practice and has practiced in a variety of areas including fire losses, construction liability, commercial and vehicle fraud, real estate defence, medical malpractice defence and personal injury defence. He also handled personal injury plaintiff cases and continued to practice in the criminal courts.Mr. Boulton is a trial lawyer and enjoys working with juries. He has appeared as counsel in the Supreme Court and the Court of Appeal of British Columbia. As the Company is limited to having four Board members, Mr. Brian Gusko has graciously decided to resign in order to free up a position on the Board to facilitate the above appointments. He will continue in his role as Chief Financial Officer of Vodis. Additionally, the Company has granted incentive stock options (the "Stock Options") pursuant to the Company's stock option plan to management of the Company (the "Optionees") entitling the purchase of an aggregate of 550,000 common shares. 350,000 of those Stock Options are exercisable at a price of $0.45 until they expire on September 3, 2024. 200,000 of those Stock Options are exercisable at $0.58 until they expire on September 8, 2024
Leseranfragen:
Vodis ist eine der renommiertesten Marken in der medizinischen Marihuanabranche Kanadas.
" alt="Avrupa’s Slivovo JV to move forward to drilling stage
Datum: 16.09.2014 - 07:59 Uhr
Sprache: Deutsch
News-ID 336313
Anzahl Zeichen: 3549
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vodis appoints Pelosi, Boulton to board
"
steht unter der journalistisch-redaktionellen Verantwortung von
Vodis Innovative Pharmaceuticals Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
